Evidence map›Paper›PMID 39072709›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2024

Design, synthesis, and evaluation of novel stilbene derivatives that degrade acidic nucleoplasmic DNA-binding protein 1 (And1) and synergize with PARP1 inhibitor in NSCLC cells.

Leyuan Chen, Zhonghao Ren, Yunze Zhang, Wenbin Hou, Yiliang Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Leyuan ChenInstitute of Radiation Medicine, Peking Union Medical College & Chinese Academy of Medical Sciences, Tianjin, China.
Zhonghao RenSchool of Life Sciences and Biopharmaceuticals, Shenyang Pharmaceutical University, Shenyang, China.
Yunze ZhangSchool of Pharmacy, Tianjin Medical University, Tianjin, China.
Wenbin HouInstitute of Radiation Medicine, Peking Union Medical College & Chinese Academy of Medical Sciences, Tianjin, China.
Yiliang LiInstitute of Radiation Medicine, Peking Union Medical College & Chinese Academy of Medical Sciences, Tianjin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Specifically inducing the degradation of acidic nucleoplasmic DNA-binding protein 1 (And1) is a promising antitumor strategy. Our previous study identified Bazedoxifene (BZA) and CH3 as specific And1 degraders and validated their activity in reversing radiotherapy resistance

Indexed as

Antineoplastic AgentsCarcinoma, Non-Small-Cell LungCell ProliferationDose-Response Relationship, DrugDrug DesignDrug Screening Assays, AntitumorLung NeoplasmsPoly (ADP-Ribose) Polymerase-1StilbenesCell Line, TumorDNA-Binding ProteinsHumansMolecular StructurePoly(ADP-ribose) Polymerase InhibitorsStructure-Activity RelationshipAntineoplastic AgentsDNA-Binding ProteinsPARP1 protein, humanPoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) Polymerase InhibitorsStilbenesAnd-1(WDHD1)antitumorDNA damage responsesynthetic lethal

Identifiers

PMID39072709
PMCPMC11288208

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.